Enzalutamide for the treatment of prostate cancer

Bibliography

• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• FDA Approval Letter for Provenge (Sipuleucel-T). Available from: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm210215.htm [Last accessed 6 January 2013]
   Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147-54
   PubMed Web of Science ®Google Scholar
• FDA Approval Information for Cabazitaxel. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-cabazitaxel [Last accessed 18 March 2012]
   Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, de Bono JS, Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48
   PubMed Web of Science ®Google Scholar
• FDA Approval for Abiraterone Acetate. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-abirateroneacetate [Last accessed 6 January 2012]
   Google Scholar
• Scher HI, Fizazi K, Saad F, Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97
   PubMed Web of Science ®Google Scholar
• FDA Approval for Enzalutamide. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-enzalutamide [Last accessed 6 January 2013]
   Google Scholar
• Taplin ME, Rajeshkumar B, Halabi S, Androgen receptor mutations in androgen-independent prostate cancer: cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21(14):2673-8
   PubMed Web of Science ®Google Scholar
• Matias PM, Carrondo MA, Coelho R, Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 2002;45(7):1439-46
   PubMed Web of Science ®Google Scholar
• Veldscholte J, Ris-Stalpers C, Kuiper GG, A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173(2):534-40
   PubMed Web of Science ®Google Scholar
• Craft N, Shostak Y, Carey M, A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5(3):280-5
   PubMed Web of Science ®Google Scholar
• Chen CD, Welsbie DS, Tran C, Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9
   PubMed Web of Science ®Google Scholar
• Li Y, Chan SC, Brand LJ, Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73(2):483-9
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324(5928):787-90
   PubMed Web of Science ®Google Scholar
• Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011;17(12):3903-12
   PubMed Web of Science ®Google Scholar
• FDA Approval Letter for Enzalutamide. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htm [Last accessed 3 January 2012]
   Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72(6):1494-503
   PubMed Web of Science ®Google Scholar
• Parker C, Heinrich D, O'Sullivan JM, Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a Phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. ASCO Meet Abstr 2012;30(5 Suppl):8
   Google Scholar
• Sartor AO, Heinrich D, Helle SI, Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A Phase III randomized trial (ALSYMPCA). ASCO Meeting Abstr 2012;30(5 Suppl):9
   Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, ARN-509 in men with high-risk non-metastatic castration resistant prostate cancer [abstract 3109]. Presented at the 2012 European Society of Medical Oncology, Vienna, Austria; 2012
   Google Scholar
• Culine S, El Demery M, Lamy P-J, Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007;178(3):844-8
   PubMedGoogle Scholar
• Medivation Press Release: PREVAIL Enrollment. Available from: http://investors.medivation.com/releasedetail.cfm?ReleaseID=680579 [Last accessed 4 January 2013]
   Google Scholar
• Ileana E, Loriot Y, Albiges L, Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100. ASCO Meet Abstr 2012;30(15 Suppl):4554
   Google Scholar
• Noonan K, Ellard S, Chi K. Clinical activity of abiraterone acetate (AA) after progression on MDV3100 in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract 925P]. Presented at the 2012 European Society of Medical Oncology Meeting, Vienna, Austria; 2012
   Google Scholar
• Bianchini D, Loriot Y, Ileana E, Abiraterone in patients with metastatic castration resistant prostate cancer progressing after docetaxel and MDV3100: a multicentre study [abstr 924P]. Presented at the 2012 European Society of Medical Oncology Meeting, Vienna, Austria; 2012
   Google Scholar
• NCT01650194. A Phase 2 study determining safety and tolerability of enzalutamide (Formerly MDV3100) in combination with abiraterone acetate in bone metastatic castration-resistant prostate cancer patients. Available from: http://clinicaltrials.gov/ct2/show/NCT01650194 [Last accessed 4 January 2013]
   Google Scholar
• Basch E, Ryan CJ, Kheoh T, The impact of abiraterone acetate (AA) therapy on patient-reported pain and functional status in chemotherapy-naive patients with progression metastatic castration-resistant prostate cancer [abstract 8950]. Presented at the 2012 European Society of Medical Oncology Meeting, Vienna, Austria; 2012
   Google Scholar
• Kohli M, Qin R, Jimenez R, Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol 2012;2012:781459
   PubMedGoogle Scholar
• Taplin ME, Bubley GJ, Shuster TD, Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332(21):1393-8
   PubMed Web of Science ®Google Scholar
• Liu W, Laitinen S, Khan S, Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15(5):559-65
   PubMed Web of Science ®Google Scholar
• Efstathiou E, Titus M, Tsavachidou D, Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012;30(6):637-43
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Conley BA, Allegra C, Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23(9):2020-7
   PubMed Web of Science ®Google Scholar